We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, ta... read more Featured Products: More products

Download Mobile App




Rapid PCR Diagnostic Test for STIs Provides Accurate Results in Less than 30 Minutes at POC

By LabMedica International staff writers
Posted on 15 Mar 2023

Three of the most common and curable sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, if left untreated, can have severe consequences for a woman's reproductive system, including infertility or potentially causing a fatal ectopic pregnancy. More...

However, there is a significant gap in STI testing accuracy and the time needed for test results, which can take up to five days. Now, a fast, polymerase chain reaction (PCR) diagnostic test rapidly tests for these three most common STIs, allowing healthcare professionals to test, talk and treat patients in a single visit.

The Visby Medical Sexual Health test is Visby Medical’s (San Jose, CA, USA) second-generation point of care (POC) test that delivers accurate results in less than 30 minutes, allowing clinicians to confidently test, talk and accurately treat in a single patient visit. Visby has developed the first and only "instrument-free" platform that brings true PCR technology to the palm of the hand. The test has a new, sleeker design that transforms a simple-to-use device by converting four steps into one while maintaining an accuracy of approximately 97%. The new device offers significant improvements in workflow, manufacturability, and reliability over its predecessor.

"We are excited that the clearance of the second generation Sexual Health Test will enable us to move production to our fully automated lines, allowing us to deliver more tests to eagerly waiting customers," said Visby Medical Senior Vice President of Operations, Mark Medlen.

“Providing more customers with access to the Visby platform will enable clinicians to make informed treatment decisions during the span of a single clinic visit. This will help reduce overtreatment and undertreatment rates, as well as the number of patients who are lost to care,” added Gary Schoolnik, MD, an infectious disease expert, Chief Medical Officer at Visby Medical, and Professor of Medicine at Stanford University. “By providing a prompt and accurate test result, the use of this test will lower the likelihood that an infected patient will develop pelvic inflammatory disease. It will expedite the treatment of that patient's sexual partner, and it will reduce the spread of sexually transmitted infections overall.”

Related Links:
Visby Medical 


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.